CI gave back ground this week — down 4.2% to $290.49 — but the underlying positioning data continues to tell a story of diminishing bearish conviction ahead of the July 30 earnings print.
The short retreat that defined last week's note has continued. Short interest has fallen a further 4.1% over the past seven days to 2.1% of free float, extending a drawdown that has now erased more than 15% of the short book over the past month. The position stood near 7.6 million shares at the start of July and is now below 5.7 million. Borrow conditions remain no obstacle to that exit: availability is extraordinarily loose at nearly 7,900% — shares available to lend vastly outnumber those already borrowed — and cost to borrow is a negligible 0.46%, up slightly on the week but well within its recent range. There is no mechanical tension keeping shorts in the trade. The ORTEX short score has eased to 33.4, down from 36.5 two weeks ago, and is now running at its lowest level in the recent window, consistent with a positioning picture that grows less charged by the session.
Options traders are not reading the week's price weakness as a sign to buy protection. The put/call ratio is 0.42, fractionally below its 20-day average of 0.44 and at the lower end of the past year's range — close to the 52-week low of 0.35. That call-heavy lean has persisted even through the pullback, which suggests the options market is treating the dip as a consolidation rather than a reversal. The z-score is just -0.47, confirming the PCR is essentially in line with recent norms: no unusual hedging demand has emerged ahead of the July 30 release.
The Street remains broadly constructive, though not without dissent. Most recent analyst action has been in the direction of target increases. Bernstein lifted its target to $381 earlier this month while maintaining Outperform. Mizuho and UBS were similarly positive in May and June, with UBS holding a $400 target. The counterweight is Barclays, which downgraded to Equal-Weight in late May with a $304 target, and Deutsche Bank, which moved to Hold around the same time. The consensus mean target of $341 implies roughly 17% upside from current levels — significant for a large-cap healthcare name. Valuation is undemanding: the stock trades at around 9x trailing earnings and 7.1x EV/EBITDA, multiples that have drifted only marginally over the past 30 days despite the price swings. The bull case rests on Evernorth's pharmacy benefit management scale and the strategic exit from the Exchange business. Bears point to margin uncertainty as Evernorth transitions to a rebate-free model and the risk that biosimilar adoption underdelivers.
The week's price action sits in contrast to some peers. CVS gained 4.2% on the week and ELV fell 7.8%, making CI's 4.2% decline look mid-pack in what was a volatile week for the managed care space. HUM slipped less than 1%. The sector-wide noise adds uncertainty to what CI's move is actually signalling on a standalone basis.
Earnings history adds a note of caution. The two most recent prints — Q4 2025 results in May and Q1 2026 — both saw the stock fall roughly 3–4% on the day of release. The five-day reaction has been similarly negative. With the stock having already pulled back 4% this week, the July 30 print is the natural next focus point: the question is whether the continued retreat in short interest and the call-skewed options market prove to be well-calibrated, or whether the earnings reaction resets the positioning picture again.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
